THERANEXUS announces its financial result for the first half of 2022
27/09/2022
(<1Mo)
THERANEXUS and BBDF finalize recruitment for phase I/II trial to evaluate Batten-1 in Batten disease
08/09/2022
(412Ko)
Semi-annual liquidity contract summary
17/07/2022
(353Ko)
Theranexus publishes its cash position as of 30 June 2022
12/07/2022
(253Ko)
Theranexus participates in several leading scientific conferences and business conventions
09/06/2022
(253Ko)
THERANEXUS publishes its 2021 full-year results and announces a shift of its strategic focus to rare neurological diseases
25/04/2022
Download PDF File (276Ko)
Information on the number of shares composing share capital
06/04/2022
Download PDF File (276Ko)
Information on the number of shares composing share capital
23/03/2022
Download PDF File (276Ko)
THERANEXUS unveils its scientific advances on the occasion of World Rare Disease Day 2022
24/02/2022
Download PDF File (544Ko)
Information on the number of shares composing share capital
10/02/2022
Download PDF File (276Ko)
THERANEXUS and BBDF start recruitment for phase I/II trial in Batten disease patients
03/02/2022
Download PDF File (373Ko)
THERANEXUS publishes its cash position as of 31 December 2021
13/01/2022
Download PDF File (355Ko)
Semi-annual liquidity contract summary
06/01/2022
Download PDF File (383Ko)
Information on the number of shares composing share capital
04/01/2022
Download PDF File (383Ko)